Clinical trial
Study Evaluating Emergency-use Tigecycline in Subjects With Resistant Pathogens.
NCT00205816 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00205816 |
|---|---|
| Title | Study Evaluating Emergency-use Tigecycline in Subjects With Resistant Pathogens. |
| Official title | An Open-label, Noncomparative, Multi-center, Emergency Use Protocol Administering Tigecycline for the Treatment of Subjects With Infections Due to Resistant Pathogens. |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Bacterial Infections |
| Intervention type | Drug |
| Interventions | Tigecycline |
| Enrollment | 26 |
| Start date | Jan 1, 2004 |
| Primary completion | Nov 1, 2005 |
| Completion | Nov 1, 2005 |
| First posted | Sep 20, 2005 |
| Last update posted | Feb 8, 2013 |
| Countries | Germany, Poland |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: